Home-Based Neurofeedback Program in Treating Participants With Chemotherapy-Induced Peripheral Neuropathy

Inclusion Criteria: * Patients must have the ability to understand and read English, sign a written informed consent, and be willing to follow protocol requirements. * Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. * Neuropathic pain score \>= 4 on a 0-10 numeric pain scale (numeric rating scale \[NRS\]) and/or grade 3 or higher neuropathic symptoms according to the National Cancer Institute's 4 point grading scale. * Neuropathic symptoms must be related to chemotherapy (in the opinion of the treating physician). * Patients must have had neuropathic symptoms for a minimum of 3 months. * No plans to change pain medication regimen during the course of the study. * Off active chemotherapy treatment for minimum of 6 months. * Hormonal (e.g., tamoxifen or arimidex, etc.) and targeted (tarceva and avastin, etc.) therapies allowed as long as they will be continued during the course of the study. * Willing to come to MD Anderson for the intake and follow up data acquisition and to receive their equipment. * Willing to allow research staff to come to their homes or to return the equipment to MD Anderson (MDA) in the case of equipment malfunction. * Have had a diagnosis of cancer treated with chemotherapy. * Live within a 50 mile radius of MD Anderson's main campus. Exclusion Criteria: * Patients who are taking any antipsychotic medications. * Patients with active central nervous system (CNS) disease, such as clinically-evident metastases or leptomeningeal disease, dementia, or encephalopathy. * Patients who have ever been diagnosed with bipolar disorder or schizophrenia. * Patients with known, previously diagnosed peripheral neuropathy from causes other than chemotherapy. * Patients who have a history of head injury or who have known seizure activity.